PH12016501175B1 - Formulations of deoxycholic acid and salts thereof - Google Patents

Formulations of deoxycholic acid and salts thereof

Info

Publication number
PH12016501175B1
PH12016501175B1 PH12016501175A PH12016501175A PH12016501175B1 PH 12016501175 B1 PH12016501175 B1 PH 12016501175B1 PH 12016501175 A PH12016501175 A PH 12016501175A PH 12016501175 A PH12016501175 A PH 12016501175A PH 12016501175 B1 PH12016501175 B1 PH 12016501175B1
Authority
PH
Philippines
Prior art keywords
deoxycholic acid
pcnt
formulations
salts
composition
Prior art date
Application number
PH12016501175A
Other versions
PH12016501175A1 (en
Inventor
Robert Emil Hodge
Jeffrey Douglas Webster
Robert M Moriarty
Original Assignee
Allergan Sales Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45569726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12016501175(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Sales Llc filed Critical Allergan Sales Llc
Publication of PH12016501175B1 publication Critical patent/PH12016501175B1/en
Publication of PH12016501175A1 publication Critical patent/PH12016501175A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

The present application is directed to an aqueous pharmaceutical composition comprising from about 0.4 pcnt w/v to less than about 2 pcnt w/v of a salt of deoxycholic acid, wherein the composition is maintained at a pH from about 8.1 to about 8.5 such that the composition is stabilized against precipitation. Also disclosed herein, are methods for stabilizing an aqueous pharmaceutical composition comprising from about 0.4 pcnt w/v to less than about 2 pcnt w/v of a salt of deoxycholic acid against precipitation, said method comprising maintaining pH of the solution from about 8.1 to about 8.5.
PH12016501175A 2011-08-23 2016-06-16 Formulations of deoxycholic acid and salts thereof PH12016501175A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/048806 WO2013028177A1 (en) 2011-08-23 2011-08-23 Formulations of deoxycholic acid and salts thereof

Publications (2)

Publication Number Publication Date
PH12016501175B1 true PH12016501175B1 (en) 2017-12-11
PH12016501175A1 PH12016501175A1 (en) 2017-12-11

Family

ID=45569726

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12016501175A PH12016501175A1 (en) 2011-08-23 2016-06-16 Formulations of deoxycholic acid and salts thereof

Country Status (18)

Country Link
JP (1) JP5919597B2 (en)
KR (5) KR20200013103A (en)
CN (3) CN108619089A (en)
AU (3) AU2011375432B2 (en)
BR (1) BR112014000547B1 (en)
CA (1) CA2842177C (en)
CR (1) CR20140053A (en)
EA (1) EA029305B1 (en)
IL (1) IL230547A (en)
IN (1) IN2014CN02188A (en)
MX (1) MX350390B (en)
MY (1) MY184277A (en)
NZ (1) NZ620040A (en)
PH (1) PH12016501175A1 (en)
SG (1) SG2014013205A (en)
UA (1) UA113522C2 (en)
WO (1) WO2013028177A1 (en)
ZA (1) ZA201401027B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
MX2018005628A (en) * 2015-11-04 2018-08-01 Kythera Biopharmaceuticals Inc Treatments of accumulated fat with deoxycholic acid and salts thereof.
US20180078621A1 (en) * 2016-09-22 2018-03-22 Kyoung Lack Lee Composition for hypotonic lipolysis and manufacturing method thereof
KR101841193B1 (en) * 2016-09-22 2018-03-22 이경락 Composition for hypotonic lipolysis and manufacturing method thereof
JP7042531B2 (en) * 2018-04-16 2022-03-28 ペンミックス リミテッド Pharmaceutical composition containing deoxycholic acid
KR102172439B1 (en) 2018-12-05 2020-10-30 송미희 Composition for lipolysis and injection composition comprising the same
KR102064864B1 (en) 2019-02-08 2020-01-10 (주)제테마 Topical injectable composition
KR102111346B1 (en) * 2019-08-20 2020-05-22 아영창 Aqueous composition with sodium deoxycholate having improved stability against precipitation
KR20220026068A (en) 2020-08-25 2022-03-04 강명범 Composition for lipolysis and injection composition comprising the same
CN116617160A (en) * 2023-07-25 2023-08-22 山东则正医药技术有限公司 Aqueous suspension, preparation method, freeze-dried powder, application and fat reduction injection

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2754709B1 (en) 1996-10-23 1999-03-05 Sanofi Sa COSMETIC COMPOSITION CONTAINING AN ANTAGONIST OF GAMMA NEUROPEPTIDE RECEPTORS AND ALPHA 2 ANTAGONISTS THAT MAY BE INCORPORATED IN SUCH A COMPOSITION
RU2224523C2 (en) * 1998-07-24 2004-02-27 Сео Хонг Ю Bile acid-containing aqueous solution and method for its preparing
US6417179B1 (en) * 1998-10-13 2002-07-09 Craig G. Burkhart Ear wax solution
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
DE10361067A1 (en) * 2003-12-22 2005-07-14 Aventis Pharma Deutschland Gmbh Medicinal lipolysis of fat accumulations
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
US7754230B2 (en) 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
ES2372499T3 (en) * 2004-05-19 2012-01-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center USE OF A DETERGENT FOR NON-SURGICAL FAT DISPOSAL.
CA2610022A1 (en) 2005-06-06 2006-12-14 Georgetown University Compositions and methods for lipo modeling
TW201011755A (en) 2008-09-10 2010-03-16 Skymedi Corp Flash memory system and its data recovery method
JP5420946B2 (en) * 2009-03-23 2014-02-19 富士フイルム株式会社 Minoxidil aqueous composition containing bile acids
EP2645099A1 (en) * 2012-03-30 2013-10-02 Phares Pharmaceutical Research N.V. Biorelevant compositions

Also Published As

Publication number Publication date
UA113522C2 (en) 2017-02-10
MX2014001495A (en) 2014-04-25
AU2016202661B2 (en) 2018-02-22
AU2016202661A1 (en) 2016-05-19
BR112014000547B1 (en) 2021-11-09
IN2014CN02188A (en) 2015-05-29
MY184277A (en) 2021-03-30
WO2013028177A1 (en) 2013-02-28
KR102073536B1 (en) 2020-02-04
KR20170075016A (en) 2017-06-30
KR101751585B1 (en) 2017-06-27
PH12016501175A1 (en) 2017-12-11
KR20190119677A (en) 2019-10-22
CA2842177C (en) 2016-07-19
CN108743522A (en) 2018-11-06
BR112014000547A2 (en) 2017-02-14
ZA201401027B (en) 2017-09-27
MX350390B (en) 2017-09-06
CN108619089A (en) 2018-10-09
EA029305B1 (en) 2018-03-30
IL230547A0 (en) 2014-03-31
EA201490175A1 (en) 2014-06-30
AU2011375432B2 (en) 2016-02-04
CN103826608A (en) 2014-05-28
NZ620040A (en) 2016-06-24
JP5919597B2 (en) 2016-05-18
KR20150000448A (en) 2015-01-02
CA2842177A1 (en) 2013-02-28
JP2014524467A (en) 2014-09-22
AU2018202807B2 (en) 2020-01-16
AU2018202807A1 (en) 2018-05-10
KR20200013103A (en) 2020-02-05
AU2011375432A1 (en) 2014-02-06
KR20180123734A (en) 2018-11-19
SG2014013205A (en) 2014-05-29
KR102034606B1 (en) 2019-10-22
KR101919269B1 (en) 2018-11-15
CR20140053A (en) 2014-06-12
IL230547A (en) 2017-02-28

Similar Documents

Publication Publication Date Title
PH12016501175B1 (en) Formulations of deoxycholic acid and salts thereof
EA201590371A1 (en) 1,4-DESIGNED PYRIDAZIN ANALOGUES AND METHODS OF TREATMENT RELATED TO SMN DEFICIENCY CONDITIONS
EP4218759A3 (en) Combination therapy
MY160249A (en) Fatty acid fumarate derivatives and their uses
UA105229C2 (en) Pharmaceutical formulation
MX340125B (en) Storage-stable 2-hydroxy-4-(methylthio) butyric acid nitrile.
MX2018001145A (en) Methods for preparation of bile acids and derivatives thereof.
MX2013010046A (en) Parenteral administration of tapentadol.
WO2012095667A3 (en) Improvements in coating technology
MY171414A (en) Compositions and methods for improving the compatibility of water soluble herbicide salts
AR109679A1 (en) ADDITION SALTS OF ACIDS FROM A BENZIMIDAZOL DERIVATIVE ((S) -4- (5,7-DIFLUOROCROMAN-4-ILOXI) -N, N, 2-TRIMETIL-1H-BENZO [D] IMIDAZOL-6-CARBOXAMIDA)
MX348977B (en) Preparation of bicyclic guanidine salts in an aqueous media.
MX2009007265A (en) Salts, aqueous liquid compositions containing salts of s-(+)-abscisic acid and methods of their preparation.
BR112016027760A2 (en) low ph synthesis method of zinc-lysine complex
MX2016001095A (en) Salts of dasatinib in crystalline form.
CY1115372T1 (en) DOSOXYLIC ACID COMPOSITIONS AND ITS SALTS
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
MX348979B (en) Plant disease control agent.
EA201890018A1 (en) COMPOSITION FOR ATTACHING HAIR FORM
PH12017500435A1 (en) A salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof
NZ613554A (en) Caprylate viral deactivation
WO2013085422A3 (en) Antitubercular composition and method for producing same
PH12018501046A1 (en) Crystals of monovalent cation salt of 3-hydroxyisovaleric acid, and method for producing said crystals
EA201992511A1 (en) COMPOSITIONS OF DESOXYCHOLIC ACID AND ITS SALTS
EA201790055A3 (en) COMPOSITIONS OF DEOXIC ACID AND ITS SALTS